GT BIOPHARMA, INC. (GTBP) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 3.48M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -16.34M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.48M | (m) | (m) | $-16.34M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $2.79M | (m) | $475.00K | $-13.34M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $3.47M | (m) | $432.00K | $-12.42M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $4.03M | (m) | (m) | $-10.59M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $4.70M | (m) | (m) | $-10.81M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $6.12M | (m) | (m) | $-13.21M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $5.80M | (m) | (m) | $-14.36M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $5.22M | (m) | (m) | $-13.77M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $5.28M | (m) | (m) | $-13.29M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $5.59M | (m) | (m) | $-13.00M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $6.47M | (m) | (m) | $-13.58M | $213.00K | (m) | (m) | -63.74× | Reported |
| 2023-09-30 | $7.95M | (m) | (m) | $-16.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $9.33M | (m) | (m) | $-20.09M | $-479.00K | (m) | (m) | (m) | Reported |
| 2023-03-31 | $8.37M | (m) | (m) | $-19.48M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $8.81M | (m) | $7.70M | $-21.26M | $8.00K | (m) | (m) | -2657.13× | Reported |
| 2022-09-30 | $12.27M | (m) | (m) | $-33.66M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $10.54M | (m) | $25.53M | $-32.59M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $10.04M | (m) | (m) | $-33.95M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $9.59M | (m) | $33.90M | $-57.52M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $3.52M | $0.00 | $10.73M | (m) | $-8.53M | (m) | (m) | (m) | Reported |
| 2021-06-30 | $2.43M | $0.00 | (m) | (m) | $-7.60M | (m) | (m) | (m) | Reported |
| 2021-03-31 | $1.80M | $0.00 | $10.08M | $34.70M | $-2.94M | (m) | (m) | (m) | Reported |
| 2020-12-31 | $485.00K | $0.00 | $269.00K | $6.76M | $-3.00M | (m) | (m) | (m) | Reported |
| 2020-09-30 | $260.00K | (m) | $-567.00K | $-5.44M | $6.86M | (m) | (m) | -0.79× | Reported |
| 2020-06-30 | $1.01M | (m) | $1.75M | $-12.35M | $6.49M | (m) | (m) | -1.90× | Reported |
| 2020-03-31 | $1.16M | (m) | $2.74M | $-13.07M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $1.67M | (m) | $5.31M | $-16.06M | $2.13M | (m) | (m) | -7.55× | Reported |
| 2019-09-30 | $2.89M | (m) | $7.71M | $-18.28M | $2.63M | (m) | (m) | -6.95× | Reported |
| 2019-06-30 | $3.33M | (m) | $6.91M | $-244.09M | $3.19M | (m) | (m) | -76.40× | Reported |
| 2019-03-31 | $6.43M | (m) | $9.20M | $-246.97M | $6.64M | (m) | (m) | -37.19× | Reported |
| 2018-12-31 | $9.07M | (m) | $9.70M | $-250.07M | $9.12M | (m) | (m) | -27.43× | Reported |
| 2018-09-30 | $7.99M | (m) | $12.41M | $-252.87M | $8.11M | (m) | (m) | -31.17× | Reported |
| 2018-06-30 | $7.41M | $0.00 | $135.09M | $-145.06M | $10.76M | (m) | (m) | -13.48× | Reported |
| 2018-03-31 | $4.40M | $0.00 | $132.31M | $-141.19M | $8.01M | (m) | (m) | -17.62× | Reported |
| 2017-12-31 | $1.07M | $0.00 | $130.12M | $-135.57M | $8.60M | (m) | (m) | -15.76× | Reported |
| 2017-09-30 | $1.16M | $0.00 | $126.68M | $-130.50M | $10.24M | (m) | (m) | -12.74× | Reported |
| 2017-06-30 | $885.00K | $0.00 | $4.06M | $-6.17M | $8.01M | (m) | (m) | -0.77× | Reported |
| 2017-03-31 | $894.00K | $0.00 | $4.34M | $-7.01M | $8.43M | (m) | (m) | -0.83× | Reported |
| 2016-12-31 | $975.00K | $0.00 | $6.59M | $-9.37M | $6.55M | (m) | (m) | -1.43× | Reported |
| 2016-09-30 | $1.25M | $0.00 | $7.75M | $-11.46M | $11.81M | (m) | (m) | -0.97× | Reported |
| 2016-06-30 | $1.23M | $0.00 | $7.58M | $-11.71M | $12.00M | (m) | (m) | -0.98× | Reported |
| 2016-03-31 | $975.00K | $20.00K | $6.72M | $-11.02M | $11.25M | 4875.00% | 33610.00% | -0.98× | Reported |
| 2015-12-31 | $1.00M | $27.00K | $3.76M | $-8.93M | $17.04M | 3703.70% | 13929.63% | -0.52× | Reported |
| 2015-09-30 | $475.00K | $60.00K | $4.45M | $-7.66M | $11.53M | 791.67% | 7416.67% | -0.66× | Reported |
| 2015-06-30 | $250.00K | $63.00K | $2.86M | $-5.43M | $13.07M | 396.83% | 4541.27% | -0.42× | Reported |
| 2015-03-31 | $250.00K | $68.00K | $2.79M | $-4.11M | $12.39M | 367.65% | 4107.35% | -0.33× | Reported |
| 2014-12-31 | $0.00 | $61.00K | $2.63M | $-2.40M | $5.15M | 0.00% | 4311.48% | -0.47× | Reported |
| 2014-09-30 | $0.00 | $69.00K | $1.00K | $-986.00K | $3.82M | 0.00% | 1.45% | -0.26× | Reported |
| 2014-06-30 | $0.00 | $249.00K | $1.00K | $-577.00K | $774.00K | 0.00% | 0.40% | -0.75× | Reported |
| 2014-03-31 | $0.00 | $280.00K | $1.00K | $-547.00K | $862.00K | 0.00% | 0.36% | -0.63× | Reported |
| 2013-12-31 | $0.00 | $368.00K | $176.00K | $-793.00K | $1.20M | 0.00% | 47.83% | -0.66× | Reported |
| 2013-09-30 | $0.00 | $546.00K | $405.00K | $-1.30M | $1.35M | 0.00% | 74.18% | -0.96× | Reported |
| 2013-06-30 | $0.00 | $483.00K | $683.00K | $-2.51M | $1.20M | 0.00% | 141.41% | -2.09× | Reported |
| 2013-03-31 | $0.00 | $429.00K | $961.00K | $-3.46M | $2.11M | 0.00% | 224.01% | -1.64× | Reported |
| 2012-12-31 | $0.00 | $342.00K | $929.00K | $-3.51M | $1.65M | 0.00% | 271.64% | -2.13× | Reported |
| 2012-09-30 | $-32.00K | $126.00K | $603.70K | $-3.82M | $1.40M | -25.40% | 479.13% | -2.74× | Reported |
| 2012-06-30 | $-32.00K | $7.00K | $391.70K | $-3.02M | $1.45M | -457.14% | 5595.71% | -2.08× | Reported |
| 2012-03-31 | (m) | $7.00K | $129.70K | $-2.47M | $462.00K | (m) | 1852.86% | -5.34× | Reported |
| 2011-12-31 | $17.00K | $26.00K | $30.70K | $-3.93M | $556.00K | 65.38% | 118.08% | -7.06× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $179.00K | $11.00K | $149.00K | $-2.50M | $513.00K | 1627.27% | 1354.55% | -4.87× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |